Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OVM-02
- Development stage
- Unknown
- Lead developer
- Oxford Vacmedix
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
OVM-02 is a therapeutic cancer vaccine developed using Oxford Vacmedix's proprietary Recombinant Overlapping Peptide (ROP) technology. The vaccine is designed to stimulate a robust immune response against survivin, a protein that is highly expressed in many types of cancer cells but is largely absent in healthy adult tissues. Survivin plays a critical role in inhibiting apoptosis and regulating cell division, making it an attractive target for immunotherapy. By utilizing the ROP platform, OVM-02 delivers multiple overlapping peptides that cover the entire sequence of the survivin protein, which facilitates the presentation of a broad range of epitopes to both CD4+ and CD8+ T cells. This approach aims to overcome the limitations of single-peptide vaccines and induce a more comprehensive and durable anti-tumor immune response. OVM-02 is currently being investigated in clinical trials for the treatment of various solid tumors, including non-small cell lung cancer (NSCLC), prostate cancer, and ovarian cancer.
- Other names
- Survivin ROP vaccineSurvivin vaccine
02
Targets
BIRC5 (Survivin)
Beyond the preview
Go deeper on OVM-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OVM-02.